SCHEMBL14034635

SCHEMBL14034635

CCCCCSc1cccc(C#N)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 4/20 0.48
DRD2 P14416 2/20 0.43
DRD3 P35462 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.42
KDM4E B2RXH2 2/20 0.42
NPC1 O15118 1/20 0.42
ALDH1A1 P00352 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
RAB9A P51151 1/20 0.42
CNR1 P21554 1/20 0.40
CNR2 P34972 1/20 0.40
HSD17B10 Q99714 3/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
MAPK1 P28482 1/20 0.39
GRM2 Q14416 1/20 0.38
MAOA P21397 2/20 0.38
MAOB P27338 2/20 0.38
TSHR P16473 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14034630 0.95 AR (0.52) ARDRD2DRD3SMN1; SMN2KDM4E
SCHEMBL18724536 0.81 SIRT2 (0.45) DRD2DRD3SMN1; SMN2HSD17B10L3MBTL1
SCHEMBL3925562 0.80 PTGS2 (0.49) ARSMN1; SMN2ALDH1A1CNR2HSD17B10
SCHEMBL5694453 0.80 KDM4E (0.56) ARSMN1; SMN2KDM4ENPC1ALDH1A1
SCHEMBL10019245 0.78 MAPK1 (0.41) SMN1; SMN2HSD17B10L3MBTL1MAPK1MAOA
SCHEMBL2979985 0.78 KDM4E (0.54) ARSMN1; SMN2KDM4ENPC1ALDH1A1
SCHEMBL7846740 0.78 KDM4E (0.54) ARSMN1; SMN2KDM4ENPC1ALDH1A1
SCHEMBL10019244 0.78 MAPK1 (0.44) SMN1; SMN2HSD17B10L3MBTL1MAPK1MAOA
SCHEMBL8386311 0.78 KDM4E (0.54) ARSMN1; SMN2KDM4ENPC1ALDH1A1
SCHEMBL7835337 0.78 KDM4E (0.54) ARSMN1; SMN2KDM4ENPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1824479-B1 PHENYLPIPERAZINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION SOLVAY PHARM BV (NL) 2008-11-05 EP disclosed
EP-1827427-B1 ARYLOXYETHYLAMINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION SOLVAY PHARM BV (NL) 2008-07-23 EP disclosed